Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of INCB054828 in metastatic or unresectable urothelial carcinoma with FGF/FGFR alterations
MOH_2017-05-11_000342Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in transitional cell carcinoma (TCC), sponsored by Incyte. Primary endpoint: Efficacy of INCB054828. Planned start Aug 2016; status: not yet recruiting.
02
Drugs
pemigatinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2017-05-11_000342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-11_000342.